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INTRODUCTION
Currently, as we approach the 50-year anniversary of Dr. Charles Huggins’ Nobel Prize for describing the hormonal de-
pendence of prostate cancer (1966), we reflect on the developments that have been made in the systemic management of
this disease. Androgen-deprivation therapy (ADT), one of the first examples of targeted cancer therapy, continues to be
the main pillar for systemic therapy of prostate cancer. By delving deeper into the pituitary-gonadal axis, extragonadal ster-
oidogenesis, and androgen receptor function, we have broadened our understanding and arsenal with the recent additions
of abiraterone and enzalutamide, while several novel agents targeting different aspects of androgen receptor signaling are
undergoing evaluation.1,2 Classic cytotoxic chemotherapies were attempted, and the microtubule was validated as a target,
with 2 taxane family agents (docetaxel, cabazitaxel) demonstrating survival benefit in metastatic, castrate-resistant prostate
cancer; and, more recently, remarkable survival benefits have been demonstrated with docetaxel in combination with
ADT in newly diagnosed metastatic disease.1,3
Although there are many critical questions across the disease landscape, the clinical challenge continues to be the
management of the metastatic stage of the disease, which is terminal for the vast majority of patients. Clearly, major thera-
peutic improvements for the metastatic population would have a large, immediate, and very palpable impact, because it is
estimated that 27,540 men will die from prostate cancer in 2015.4
Because metastatic disease is the driver of morbidity and mortality, defining its origin is crucial. A metastatic deposit
must survive release from the primary site into the blood stream, tolerate the circulatory environment, avoid the immune
system, cross a vascular endothelium, adhere to the extracellular matrix in a new site, and develop a dedicated blood supply
to support growth.5 Building from this basic biologic paradigm, efforts to diminish growth factor availability and to inter-
rupt cell-extracellular matrix binding along with antiangiogenic therapies have been attempted.
Tumor Microenvironment
The seed and soil interaction has been a focus area for cancer therapy development in general and for prostate cancer in par-
ticular. Bone, being the hallmark of prostate cancer metastasis, is a dynamic structure that undergoes constant destruction
and rebuilding to manage an individual’s physical demands and metabolic needs. This homeostasis in part depends on
growth factors (insulin-like growth factor, transforming growth factor-b), chemotaxic factors (stromal cell-derived factor
1, C-X-C chemokine receptor type 4), and the maintenance of specific cell-cell and cell-extracellular matrix interactions.
Prostate cancer (among others) uses this nurturing environment and can reside in both dormant and active states. To date,
targeting some of the growth factor environment by inhibiting the insulin-like growth factor-1 receptor has not been effec-
tive.5 The adherence of prostate cancer to the extracellular matrix is based on the interaction between integrin proteins on
the cell surface and the matrix. Targeting this interaction also has not been successful to date.6,7
Angiogenesis
Angiogenesis and its role in creating and supporting the tumor microenvironment was first proposed by Judah Folkman
in 19718 and has grown to both biologic and clinical relevance for a variety of solid tumors with US Food and Drug
Administration-approved indications. The therapeutic premise is that, if the blood supply to the tumor is halted, then the
tumor should die or, at a minimum, stop growing, spreading, and seeding. Tumor blood vessels arise through the stimula-
tion of native vessel endothelium to proliferate through the vascular endothelial growth factor (VEGF) pathway. This
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pathway begins with extracellular ligand (ie, VEGF-A,
VEGF-B) activating one of several VEGF receptors (ie,
VEGFR1, VEGFR2). This causes receptor heterodimeri-
zation and/or homodimerization with autophosphoryla-
tion of the intracellular domain. The active kinase
amplifies its original signal by triggering a multitude of
signal pathways, such as phosphatidyl-inositol 3-kinase
(PI3K), proto-oncogene tyrosine-protein kinase (SRC),
or phospholipase Cc-protein kinase C (PLC-c-PKC)
pathways. These lead to the activation of migratory pro-
teins and proliferative pathways while down-regulating
apoptotic pathways.9
Drugs have targeted several steps in the angiogenic
process. The classic example is bevacizumab, a monoclonal
antibody that functions as a ligand sink for VEGF-A by
binding it in circulation. Bevacizumab was tested in a
blinded phase 3 trial by adding it to docetaxel.10 The beva-
cizumab/docetaxel combination had no impact on overall
survival compared with docetaxel (22.6 months vs 21.6
months). Aflibercept, an antibody-based VEGF receptor
mimetic, also acts upstream of receptor activation by bind-
ing a variety of receptor ligands (ie, VEGF-A, VEGF-B,
and placental growth factor). The hope was that depletion
of more ligands would enhance the antitumor effect. How-
ever, it also was disappointing, because it produced no over-
all survival benefit (22.2 months vs 21.2 months).11 Rather
than depleting the ligand, another approach was to inhibit
the ligand-receptor interaction. The monoclonal antibody
ramucirumab binds VEGFR2 directly, hence sterically in-
hibiting it from ligand. This drug was recently approved in
gastric cancer and had preliminary, potentially promising
data based on a noncomparative phase 2 trial in combina-
tion with mitoxantrone.12 Inhibiting the initiating ligand-
receptor interaction may yield results, but the challenges lie
in the redundancy in both ligand and receptor pool; and,
when 1 pathway slows, another amplifies to replace its mi-
togenic effect.
The VEGF pathway was also targeted by stopping
downstream intracellular phosphorylation events. These
are the tyrosine kinase inhibitors. The best studied in
prostate cancer is the nonselective kinase inhibitor suniti-
nib, which stops VEGFR-2 phosphorylation. In a phase 3
trial, it did not improve survival (13.1 months vs 11.8
months).13 Other inhibitors have been investigated (sora-
fenib, cediranib, cabozantinib), yet none produced con-
firmed, meaningful clinical activity or benefit.
These cumulative failures with agents targeting
angiogenesis and related pathways likely reflect the diverse
signaling environment driven by advanced-stage disease,
plasticity of the cell to be stimulated in a variety of ways,
selective amplification of weak signals, lack of predictive
biomarkers to allow for better patient selection, and
potentially the disease setting/burden. It is within this
context that the article in the current issue of Cancer by
Pasqualini and colleagues is of interest.14 These investiga-
tors report their data on another novel mechanistic class
by targeting the endothelial vascular signature of prostate
cancer metastasis. It is believed that these unique vascular
surface signatures (“zip codes”) are created when tumor
cells seed a site and stimulate new vasculature to grow.
Through an earlier in vivo phage library screen developed
by the group, the interleukin 11 receptor a (IL-11Ra) was
up-regulated in vascular endothelium associated with
prostate cancer.14 By creating a chimeric peptide with the
IL-11Ra–binding domain fused to an apoptosis-inducing
peptide motif, they sought to selectively target the intratu-
mor vasculature while sparing nontumor-associated ves-
sels. This is similar to antibody-drug conjugates currently
in use for other malignancies except with a smaller recog-
nition moiety and protein cascade of apoptosis compared
with direct cytotoxins.
After developing this chimeric peptidomimetic drug
(bone metastasis-targeting peptidomimetic-11 [BMTP-
11]), the investigators first characterized its preclinical ef-
ficacy. By using 3 cell lines that reflected different clinical
scenarios (androgen-sensitive, castrate-resistant, and
bone-predominant disease), intravenous BMTP-11 was
given weekly, and tumor volume was monitored. BMTP-
11 stalled the growth in each scenario, and the strongest
response was observed in the bone-predominant cell line,
which had the highest expression of IL-11Ra. Tissue dis-
tribution, serum stability, and pharmacokinetic parame-
ters were determined in preparation for toxicity
evaluation in nonhuman primates. Renal injury became
apparent, with discoloration of the kidneys and tubule
destruction, but BMTP-11 was deemed safe to continue.
The first-in-man studies with dose escalation were
done in patients with widely metastatic bone disease, and
biopsies were used to confirm the presence of bone metas-
tases. The expression of IL-11Ra in initial confirmatory
bone marrow biopsies revealed enrichment of the receptor
by immunohistochemistry. A bone marrow biopsy was
repeated after the first infusion, and immunohistochemis-
try and mass spectrometry confirmed the presence of
BMTP-11. Terminal deoxynucleotidyl transferase dUTP
nick-end labeling confirmed apoptosis-mediated death,
hence completing the localization and predicted effect
loop. By using the 6 patients on study, an escalation dose
model was done. This began at 18 mg/m2 and then was
increased to 36 mg/m2 after the first dose was tolerated
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well by 2 patients for 4 treatments each. At this higher
dose, patient 3 had grade 3 renal toxicity; therefore, the
protocol was amended for a 27 mg/m2 dosing cohort.
Three more patients were treated at this intermediate dose
but did not complete the 4 planned cycles because of ei-
ther progression or renal toxicity. With the small sample
size, efficacy cannot be established. It is interesting that 1
patient had symptomatic and biochemical improvement,
but his disease relapsed quickly when the medication was
withdrawn. That patient had the least renal toxicity, sug-
gesting the possibility of pharmacogenomic variability;
however, the data is limited at this time.
Renal dysfunction seems to be the primary adverse
event, because 33% of patients had grade 2 or 3 glomeru-
lar filtration rate changes. More intravenous fluids were
added but still did not negate the effect. The injury was re-
versible but clearly raises concern about longer durations
of treatment and feasibility in the prostate cancer popula-
tion. This effect is not common among other peptidomi-
metics (argatroban, human immunodeficiency virus-
protease inhibitors), arguing against a class affect. The
researchers observe the same tubular injury with their
other engineered peptidomimetic drugs, which share the
apoptotic motif.16 They discuss engineering a different
chemical moiety to avoid this while also suggesting dose
or schedule modifications. Clearly these are important
options to pursue.
Although bone metastasis is the “clinical” hallmark
of prostate cancer, autopsy data highlight the promiscu-
ous nature of the disease and scope of its spread, stressing
the need for more than just targeting of bone.17 It will be
critical to evaluate the same technology in the context of
lymph node metastases and other organ metastasis to
determine whether or not the “zip code” signatures and
targeting methods described here are applicable and
effective.
Pasqualini and colleague’s study is extensive in its
scope and novel in its scientific base. It builds on previous
rational, mechanistic drug-development strategies, yet is
in a new mechanistic realm, hopefully devoid of the re-
dundancy observed in the other vascular-targeted thera-
pies. However, a key issue that needs to be addressed and
optimized is the feasibility of human application with the
toxicities mentioned above.
It is clear from the prior clinical research on angio-
genesis and other pathways in metastatic, castration-
resistant prostate cancer that these tumors are smart: they
adapt, and they cannot be forced to become dependent on
a single pathway, nutrient, or environment. Despite the
disappointing results to date, targeting tumor angiogene-
sis is still logical in this disease; however, it is clear that
more critical research is needed to better understand the
biologic context of tumorigenesis, metastasis/seeding, and
the microenvironment in prostate cancer to better guide
our drug development and clinical research.
Performing high-quality, informative clinical trials
is not easy but very critical as is the case in this trial. It is
ultimately the brave patients and families; like the brain
dead patient who underwent the peptide library infusion
and biopsy and the patients who participated in this phase
0 trial and underwent multiple bone biopsies that allow us
to find the next best therapies.
It is challenging to predict, at the onset of a new
field, whether the pathway is worthwhile; however, this
report clearly highlights an interesting and novel target
and a directed strategy that need further exploration. After
more than 7 decades of androgen-signaling research and
over 4 decades of angiogenesis research, we are still learn-
ing. We continue to be puzzled by the frequent mismatch
between preclinical observations and clinical outcomes.
Therefore, addressing apoptosis to tumor zip codes as an
overarching principle, exemplified in this case by Dr. Pas-
qualini and her team’s approach, continues to be a goal
that we all (and no doubt Drs. Huggins and Folkman)
would appreciate.
FUNDING SUPPORT
No specific funding was disclosed.
CONFLICT OF INTEREST DISCLOSURES
Dr. Hussain reports grants fromMedivation, Lilly-ImClone, Bayer,
Genentech, andMerck KGaA to the University of Michigan.
REFERENCES
1. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men
with metastatic castration-resistant prostate cancer: American Society
of Clinical Oncology and Cancer Care Ontario clinical practice
guideline. J Clin Oncol. 2014;32:3436-3448.
2. Taplin M-E. Activity of galeterone in castrate-resistant prostate can-
cer (CRPC) with C-terminal AR loss: results from ARMOR2. Paper
presented at: 26th EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics; November 18-24, 2014; Barce-
lona, Spain.
3. Sweeney C, Chen Y-H, Carducci MA, et al. Impact on overall sur-
vival (OS) with chemohormonal therapy versus hormonal therapy
for hormone-sensitive newly metastatic prostate cancer (mPrCa): an
ECOG-led phase III randomized trial [abstract]. J Clin Oncol. 2014;
32(suppl 5). Abstract LBA2.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J
Clin. 2015;65:5-29.
5. De Bono JS, Piulats JM, Pandha HS, et al. Phase II randomized
study of figitumumab plus docetaxel and docetaxel alone with cross-
over for metastatic castration-resistant prostate cancer. Clin Cancer
Res. 2014;20:1925-1934.
6. Alva A, Slovin S, Daignault S, et al. Phase II study of cilengitide
(EMD 121974, MSC 707544) in patients with non-metastatic cas-
tration resistant prostate cancer, NCI-6735: a study by the DOD/
Editorial
2298 Cancer July 15, 2015
PCF prostate cancer clinical trials consortium. Invest New Drugs.
2012;30:749-757.
7. Hussain M, Miler K, Rybicka I, Bruns R. Primary outcomes of the
placebo-controlled phase 2 study PERSEUS (NCT01360840) inves-
tigating 2 dose regimens of abituzumab (DI17E6, EMD 525797) in
the treatment of chemotherapy-na€ıve patients (pts) with asymptom-
atic or mildly symptomatic metastatic castration-resistant prostate
cancer (mCRPC) [abstract]. J Clin Oncol. 2014;32(suppl 5). Abstract
5030.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J
Med. 1971;285:1182-1186.
9. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF recep-
tor signalling—in control of vascular function. Nat Rev Mol Cell
Biol. 2006;7:359-371.
10. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind,
placebo-controlled phase III trial comparing docetaxel and predni-
sone with or without bevacizumab in men with metastatic
castration-resistant prostate cancer: CALGB 90401. J Clin Oncol.
2012;30:1534-1540.
11. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in
combination with docetaxel and prednisone for treatment of men
with metastatic castration-resistant prostate cancer (VENICE): a
phase 3, double-blind randomised trial. Lancet Oncol. 2013;14:760-
768.
12. Hussain M, Rathkopf DE, Liu G, et al. A phase II randomized
study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC-
1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients
(pts) with metastatic castrate-resistant prostate cancer (mCRPC) after
disease progression (PD) on docetaxel (dCT) therapy [abstract].
J Clin Oncol. 2012;30(suppl 5). Abstract 97.
13. Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-
controlled, phase III trial of sunitinib plus prednisone versus predni-
sone alone in progressive, metastatic, castration-resistant prostate can-
cer. J Clin Oncol. 2014;32:76-82.
14. Pasqualini R, Milikan RE, Christianson DR, et al. Targeting the
interleukin-11 receptor a in metastatic prostate cancer: a first-in-
man study. Cancer. 2015;121:2411-2421.
15. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the
human vasculature by phage display. Nat Med. 2002;8:121-127.
16. Barnhart KF, Christianson DR, Hanley PW, et al. A peptidomimetic
targeting white fat causes weight loss and improved insulin resistance
in obese monkeys [serial online]. Sci Transl Med. 2011;3:108ra112.
17. Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T.
Metastatic patterns of prostatic cancer. Correlation between sites and
number of organs involved. Cancer. 1984;54:3078-3084.
Editorial/Reichert and Hussain
Cancer July 15, 2015 2299
